Person:
LERMİ, NİHAL

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

LERMİ

First Name

NİHAL

Name

Filters

2022 - 20233
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Paradoxical reactions, especially psoriasis in rheumatology patients receiving biologic therapy from the treasure database: A 5-year follow-up study
    (BMJ Publishing Group, 2022-06-01) Yağız, Burcu; Lermi, Nihal; Coşkun, B. Nejdet; Dalkılıç, Ediz Hüseyin; Kiraz, S.; Ertenli, A. I.; Bilgin, E.; Yılmaz, R.; Ateş, A.; Tufan, A.; Mercan, R.; Cinakli, H.; Akar, S.; Kaşifoğlu, T.; Türk, S. M.; Gönüllü, E.; Erden, A.; Beş, C.; Emmungil, H.; Kalyoncu, U.; Pehlivan, Y.; TReasure; YAĞIZ, BURCU; LERMİ, NİHAL; COŞKUN, NEJDET; DALKILIÇ, HÜSEYİN EDİZ; 0000-0003-0298-4157; JHC-5173-2023; FGB-0552-2022; AAG-7155-2021; JQW-5031-2023
  • No Thumbnail Available
    Publication
    What predicts the recurrence in idiopathic granulomatous mastitis?
    (Springer London Ltd, 2023-06-10) Lermi, Nihal; Ekin, Ali; Ocak, Tuğba; Bozkurt, Zeynep Yılmaz; Ötegeçeli, Mehmet Akif; Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; LERMİ, NİHAL; EKİN, ALİ; OCAK, TUĞBA; Bozkurt, Zeynep Yılmaz; ÖTEGEÇELİ, MEHMET AKİF; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0003-3692-1293; 0000-0003-3692-1293; 0000-0002-7714-7786; GXH-1905-2022; JQW-5031-2023; AAG-7155-2021; FGB-0552-2022; FPM-3131-2022; IUR-9292-2023; IUS-1387-2023; IRX-3951-2023; JHC-5173-2023
    Introduction Idiopathic granulomatous mastitis (IGM) is a rarely seen chronic and benign disease of the breast. IGM usually emerges in women between 30 and 45 years of age and within the first 5 years after lactation. There is no consensus on the treatment of the disease. Steroids, immunosuppressive agents such as methotrexate and azathioprine, antibiotics, and surgical and conservative treatments can be preferred. In the present study, it was aimed to demonstrate the treatment options and follow-up data of the patients with IGM and to investigate the effective factors on recurrence if developed in the follow-up period.Materials and method The data of 120 patients diagnosed with idiopathic granulomatous mastitis were evaluated for this cross-sectional retrospective study. The demographic, clinical, treatment, and follow-up features of the patients were obtained from the file records.Results The median age value of the 120 female patients included in the study was 35 (24-67) years. Of the patients, 45%, 79.2%, 49.2%, and 15% had a past history of surgical intervention, steroid use, methotrexate use, and azathioprine use, respectively. Recurrent lesion developed after the treatment in 57 (47.5%) patients. The recurrence rate was 66.1% in the patients who underwent surgical intervention in the initial treatment. There was a statistically significant difference between the patients with and without recurrence regarding the presence of abscess, the presence of recurrent abscess, and having surgical intervention as the initial treatment in the past history. The rate of having surgery was statistically significantly higher compared with the administration of steroid therapy alone and the combination of steroid and immunosuppressive therapy in the initial treatment of the patients who developed recurrence. The rate of having surgery together with the administration of steroid and immunosuppressive therapy was statistically significantly higher than the administration of steroid and immunosuppressive therapies.Discussion Our study showed that surgical intervention and the presence of abscess increased recurrence in the treatment of IGM.
  • No Thumbnail Available
    Publication
    The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study
    (Oxford Univ Press, 2023-06-24) Yağız, Burcu; Lermi, Nihal; Coşkun, Belkıs N.; Dalkılıç, Ediz; Kiraz, Sedat; Erden, Abdülsamet; Ertenli, İhsan; Duran, Emine; Bilgin, Emre; Yılmaz, Recep; Ateş, Aşkın; Tufan, Abdurrahman; Küçük, Hamit; Mercan, Rıdvan; Cinakli, Haluk; Akar, Servet; Bilge, Nazife S. Yaşar; Kaşifoğlu, Timuçin; Türk, Sümeyye M.; Gönullü, Emel Orge; Bes, Cemal; Kanitez, Nilüfer Alpay; Emmüngil, Hakan; Kalyoncu, Umut; Pehlivan, Yavuz; YAĞIZ, BURCU; LERMİ, NİHAL; COŞKUN, BELKIS NİHAN; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Romatoloji Bilim Dalı; 0000-0003-0298-4157 ; JQW-5031-2023; FGB-0552-2022; AAG-7155-2021; CMF-4757-2022; AAG-8227-2021
    Objectives The objectives of this study were to assess the clinical characteristics, predictive factors, and practical algorithms of paradoxical reactions (PRs), specifically paradoxical psoriasis (PP). Methods The TReasure database is a web-based prospective observational cohort comprised of patients with RA and SpA from 17 centres around Turkey since 2017. A cohort study and a case-control study nestled within the cohort were identified. Results In total, 2867 RA and 5316 SpA patients were evaluated. The first biologic agent was found to have caused PRs in 60% of the 136 patients (1.66%) who developed the PRs. The median time interval between the PRs and biological onset was 12 months (range 1-132 months, mean 21 months). The most common types of PP, constituting 92.6% of PRs, were pustular (60.3%) and palmoplantar (30.9%). Adalimumab (30.9%), infliximab (19%) and etanercept (17.4%) were the most common agents causing the PP. In the treatment of most PP patients (73.2%), switching biologic agents was favoured, with TNF inhibitor (TNFi) chosen in 46.03% and non-TNFi in 26.9% of cases. The three most frequently selected drugs were etanercept (24.6%), secukinumab (9.5%) and adalimumab (8.7%). Only 5.17% of patients who switched to another TNFi showed progression. The odds ratios (s) for SSZ, HCQ, and LEF use were significantly higher in RA controls than in PP patients (P = 0.033, OR = 0.15; P = 0.012, OR = 0.15; and P = 0.015, OR = 0.13, respectively). In the PP group with SpA, the number of smokers was significantly higher (P = 0.003, OR: 2.0, 95% CI: 1.05, 3.81). Conclusion Contrary to expectations based on earlier research suggesting that paradoxical reactions develop with the class effect of biological agents, the response of patients who were shifted to another TNFi was favourable.